

Award Number:
W81XWH-08-1-0384

TITLE:
The Contribution of Genotype to Heterotopic Ossification after Orthopaedic Trauma

PRINCIPAL INVESTIGATOR:
Erika J. Mitchell, M.D.

CONTRACTING ORGANIZATION:
Vanderbilt University Medical Center
Nashville, TN 37232

REPORT DATE:
May 2009

TYPE OF REPORT:
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 14-05-2009			2. REPORT TYPE Annual		3. DATES COVERED 15 MAY 2008-14 APR 2009	
4. TITLE AND SUBTITLE The Contribution of Genotype to Heterotopic Ossification after Orthopaedic Trauma					5a. CONTRACT NUMBER W81XWH-08-1-0384	
					5b. GRANT NUMBER	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Erika J. Mitchell, M.D. Email: erika.j.mitchell@vanderbilt.edu					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Medical Center Nashville, TN 37232					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT None provided.						
15. SUBJECT TERMS None provided.						
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	19b. TELEPHONE NUMBER <i>(include area code)</i>			

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	2
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusion.....	4
References.....	5
Appendices.....	8

INTRODUCTION

Historically, heterotopic ossification (HO) and hypertrophic callus formation has been associated with traumatic brain injury (TBI), spinal cord injury and severe burns. Heterotopic ossification is a distinct skeletal complication (phenotype) in military and civilian trauma patients with high velocity fractures. Despite an incidence of 11-25% in multiply injured civilian patients and patients, and 63% in combat related amputations, the phenomenon is still poorly understood.¹⁻⁴

Data suggests that bone remodeling is subject to significant autonomic control via beta-2 (β_2) adrenergic receptors on osteoblasts and involves the hormone leptin.^{5,6} Patients with multiple trauma and/or brain injury frequently have autonomic nervous system dysfunction,^{7,8} but the potential link to heterotopic bone formation has not yet been studied. Furthermore, not all patients with similar injury patterns and demographics develop HO, suggesting a genetic component, which under the appropriate environmental and physiologic conditions, predisposes some patients to the complication.

The process of heterotopic bone formation around fractures and ectopic bone around joints and soft tissue unrelated to trauma appear to be the same phenomenon.⁹⁻¹¹ This created a unique opportunity to prospectively monitor patients with traumatic fractures using serial radiographs for heterotopic bone formation and to match these with controls based on demographics and injuries. We have now examined 1095 patients over a two year period for HO and single nucleotide polymorphisms that may be associated with HO.

Certain individuals are genetically predisposed to complications which may be triggered by environmental influences.¹² While this phenomenon is often associated lung cancer and cigarette smoke, there is also evidence of genetic predisposition to common skeletal diseases such as osteoporosis.^{13,14} We are beginning to identify genes that may predispose patients to HO should they have a traumatic injury to the musculoskeletal system.

Understanding the genetic factors underlying a complication allows stratification of “at risk” patients and the subsequent development of new therapy. Standard treatment regimens are not benign, and presently include the use of radiation therapy and anti-inflammatory medications, such as indomethacin. Patients with acetabular and long bone fractures given indomethacin for HO prophylaxis had a significantly higher rate of nonunion (26% versus 7%) than controls.¹⁵ Radiation therapy has fewer side effects, however it must be administered within 72 hours of injury, limiting its use in a combat environment.¹⁶⁻¹⁸ Consequently, our current therapeutic strategies have limitations and stratification of patients by risk of HO may have important implications for clinical care.

At the end of Year One, we have achieved most of our expected milestones. This has culminated in an abstract that has been accepted for a podium presentation at the Basic Science Forum at the Orthopaedic Trauma Association meeting in October 2009.

BODY

Aim 1: To examine the relationship of genetics to the Heterotopic Ossification (HO) phenotype.

Data from 1095 consecutive trauma patients over a 24 month period have thusfar been examined. These patients all have DNA samples in our genetics repository and radiographic records of fracture or amputation with a minimum of 8 weeks of radiographic follow up. Radiographic review demonstrated heterotopic bone formation in 108 (10%) of these patients. This is a percentage that is consistent with rates published in the literature for civilian populations. The anatomic subsets are as follows: Femur 29%; Pelvis 46%; Humerus 11%; Forearm 7%; Tibia 5%; Elbow 2%. The remaining patients without HO were used as the comparison group.

DNA was extracted from all patients using the PUREGENE system (Gentra Systems Inc., Minneapolis, MN). Sixty one single nucleotide polymorphisms were examined including genes associated with autonomic, metabolic and inflammatory pathways (see Appendix). Genotyping was done using 5' allelic discrimination assay (Applied Biosystems Inc., Foster City, CA) and mass spectroscopy (Sequenom Inc., San Diego, CA).

Sixty one SNPs were examined, and of these, 3 polymorphisms reached significance for association with HO: rs1042714 (a β_2 -Adrenergic Receptor, ADRB2), rs4986791 (Toll-Like Receptor 4, TLR4), and rs4986791 (Complement Factor H, CFH). ADRB2 was associated with increased risk of developing HO, and TLR4 and CFH were associated with decreased risk. Interestingly, these are genes that are associated with three distinct physiologic pathways: 1. The adrenergic system, 2. Immune signaling, and 3. Inflammation. The SNPs associated with HO have been previously associated with non-skeletal trauma outcomes.

Gene, (SNP)	Population freq of effect genotype	Pathway	Odds Ratio, (95% CI)	p-value
CFH, (CC vs. TT)	39.0%	Complement Activation	0.52 (0.29 - 0.94)	0.03
ADRB2, (CC vs GG)	15.7%	Adrenergic Nervous System	1.86 (1.05 - 3.29)	0.03
TLR4, (CC vs. CT)	10.2%	Innate immunity activation	0.42 (0.16 - 1.00)	0.05

Accrual and genetic extraction are ongoing. At present we have extracted DNA from 3000 specimens already have 2000 more in our repository awaiting extraction. Data from these patients will be added to the present data on a continual basis.

Aim 2: To determine the environmental effect (ie, injury severity, traumatic brain injury, medications) on phenotype expression.

Data from the trauma registry (TRACS) is being compiled to include associated injuries (head, chest, abdomen, etc) as well as information on medications, pre-existing medical conditions, and demographics from the electronic medical record for the current cohort of patients. This is being de-identified as we compile the data. We will begin statistical analysis to determine gene-environment interactions once we identify at least 200 HO patients to provide power to the statistics. We expect to be able to do this starting in month 18 as planned.

Aim 3: To determine clinical biomarkers which predict the HO phenotype.

Data capture has already been performed on the patients in our current cohort. We will compile this data with environmental data in Aim 2 as we complete genotyping.

KEY RESEARCH ACCOMPLISHMENTS

- Reviewed 1095 radiographs for presence of HO in a trauma population
- Identified 108 patients with the HO phenotype
- DNA extraction performed on these patients
- Examination of 61 SNPs in this population for inflammatory, immune and bone markers
- Found statistical significance for 3 SNPs (CFH, TRL4 and ADBR2) in association with formation or protection from HO
- Data accepted for presentation at the Annual Orthopaedic Trauma Association Basic Science Forum

REPORTABLE OUTCOMES

We have demonstrated an association between three polymorphisms and heterotopic ossification. TLR4, CFH and AD2BR are polymorphisms that have been noted in prior studies for their association with morbidity in trauma. These genes mediate physiologic processes that are not yet directly linked bone remodeling.

We have been accepted for podium presentation of our early findings at the Basic Science Forum at the Orthopaedic Trauma Association annual meeting in October 2009. This abstract is attached in the Appendices.

We have submitted a grant proposal to NIAMS/NIH in response to the GO Grant Opportunity to build on this research as we identify more SNPs, and increase our sample size.

CONCLUSION

We have identified three polymorphic variations that are associated with the development of heterotopic ossification. These include SNPs that are known to be involved in the inflammatory process (TRL4 and CFH) and autonomic regulation (β_2 Adrenergic Receptor). In addition, these SNPs have shown significance in other studies associating these genotypes with morbidity and mortality after trauma. This early data adds evidence to the theory that there is a mechanism of central nervous system control of bone remodeling through autonomic and inflammatory processes. Heterotopic ossification may be related to autonomic dysregulation secondary to genetic predisposition and/or head injury. This study provides evidence for at least three distinct pathways associated with HO, the adrenergic system, immune signaling and the alternative complement system. Over the next two years, we will add more specimens in the analysis, and also include more candidate genes. We will also begin to add the clinical data including

associated injuries and physiologic markers such as heart rate variability to determine clinical markers of these genetic differences that may relate to the systemic response to trauma in certain individuals and that may also affect the remodeling of bony injury. Furthermore, we are seeking funding to expand this project to a genome wide association study for a more thorough understanding of the genetic influences and interactions in bone remodeling.

REFERENCES

- (1) Kaplan FS, Glaser DL, Hebela N, Shore EM. Heterotopic ossification. *J Am Acad Orthop Surg.* 2004;12:116-125.
- (2) Morley J, Marsh S, Drakoulakis E, Pape HC, Giannoudis PV. Does traumatic brain injury result in accelerated fracture healing? *Injury.* 2005;36:363-368.
- (3) Rigaux P, Benabid N, Darriet D et al. Study of serum factors potentially involved in the pathogenesis of heterotopic bone formation after severe brain injury. *Joint Bone Spine.* 2005;72:146-149.
- (4) Smith R. Head injury, fracture healing and callus. *J Bone Joint Surg Br.* 1987;69:518-520.
- (5) Elefteriou F. Neuronal signaling and the regulation of bone remodeling. *Cell Mol Life Sci.* 2005;62:2339-2349.
- (6) Takeda S. Central control of bone remodeling. *Biochem Biophys Res Commun.* 2005;328:697-699.
- (7) Woolf PD, Cox C, Kelly M, Nichols D, McDonald JV, Hamill RW. The adrenocortical response to brain injury: correlation with the severity of neurologic dysfunction, effects of intoxication, and patient outcome. *Alcohol Clin Exp Res.* 1990;14:917-921.
- (8) Morris JA, Jr., Norris PR, Waitman LR, Ozdas A, Guillaumondegui OD, Jenkins JM. Adrenal insufficiency, heart rate variability, and complex biologic systems: a study of 1,871 critically ill trauma patients. *J Am Coll Surg.* 2007;204:885-892.
- (9) Boes M, Kain M, Kakar S et al. Osteogenic effects of traumatic brain injury on experimental fracture-healing. *J Bone Joint Surg Am.* 2006;88:738-743.
- (10) Perkins R, Skirving AP. Callus formation and the rate of healing of femoral fractures in patients with head injuries. *J Bone Joint Surg Br.* 1987;69:521-524.
- (11) Spencer RF. The effect of head injury on fracture healing. A quantitative assessment. *J Bone Joint Surg Br.* 1987;69:525-528.
- (12) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007;447:661-678.
- (13) Fossum E, Hoieggen A, Reims HM et al. High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men. *Blood Press.* 2004;13:89-94.
- (14) Wright CE, O'Donnell K, Brydon L, Wardle J, Steptoe A. Family history of cardiovascular disease is associated with cardiovascular responses to stress in healthy young men and women. *Int J Psychophysiol.* 2007;63:275-282.
- (15) Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. *J Bone Joint Surg Br.* 2003;85:700-705.
- (16) Coventry MB, Scanlon PW. The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. *J Bone Joint Surg Am.* 1981;63:201-208.
- (17) Lo TC. Radiation therapy for heterotopic ossification. *Semin Radiat Oncol.* 1999;9:163-170.

(18) Seegenschmiedt MH, Keilholz L, Martus P et al. Prevention of heterotopic ossification about the hip: final results of two randomized trials in 410 patients using either preoperative or postoperative radiation therapy. *Int J Radiat Oncol Biol Phys.* 1997;39:161-171.

The Genetics of Heterotopic Ossification: Insight into the Bone Remodeling Pathway

Erika Mitchell MD¹, Jeffrey Canter MD², Patrick Norris MD², Judith Jenkins RN², John Morris MD²

Vanderbilt University Medical Center, ¹Division of Orthopaedic Trauma, ²Division of Trauma, Nashville, TN

PURPOSE: Heterotopic ossification (HO) occurs in 12-20% of civilian and 63% of military fracture patients resulting in significant morbidity (pain, reduced function, re-operation). Others have demonstrated bone remodeling following fracture is regulated by numerous physiologic pathways (inflammation, autonomic nervous system, glucose metabolism) and environmental conditions (open fracture, wound classification, traumatic brain injury, and medications). This study presents the first association between HO and the human genome. **Hypothesis:** Genetic variation in multiple physiologic pathways modifies bone remodeling and in some individuals increases their risk of HO after fracture.

METHODS: Over 24 months, 1095 consecutive trauma patients were admitted to the ICU, DNA obtained, and subsequent radiographs reviewed for HO. 108 patients (10%) were identified with HO and compared to 982 non-HO patients. DNA was extracted from the 1095 patients using the PUREGENE system. (Gentra Systems Inc., Minneapolis, MN.) 61 SNPs representing a variety of structural, metabolic and autonomic pathways were examined. Genotyping was done via 5' allelic discrimination assay (Applied Biosystems Inc., Foster City, CA) and mass spectroscopy (Sequenom Inc., San Diego, CA). Multivariate logistic regression was used to analyze each SNP independently while adjusting for severity of injury (as measured by TRISS).

RESULTS: Of 61 SNPs, 3 polymorphisms reached significance for association with HO: rs1042714 (a β_2 -Adrenergic Receptor, ADRB2), rs4986791 (Toll-Like Receptor 4, TLR4), and rs4986791 (Complement Factor H, CFH). ADRB2 was associated with increased risk of developing HO, and TLR4 and CFH were associated with decreased risk.

Gene, (SNP)	Population freq of effect genotype	Pathway	Odds Ratio, (95% CI)	p-value
CFH, (CC vs. TT)	39.0%	Complement Activation	0.52 (0.29 - 0.94)	0.03
ADRB2, (CC vs GG)	15.7%	Adrenergic Nervous System	1.86 (1.05 - 3.29)	0.03
TLR4, (CC vs. CT)	10.2%	Innate immunity activation	0.42 (0.16 -1.00)	0.05

CONCLUSIONS: The genome may affect bone remodeling after fracture, in some cases resulting in heterotopic ossification.

- 1) Three distinct pathways were associated with risk for HO: the adrenergic system, immune signaling and the alternative complement system
- 2) This preliminary data reinforces previous observations linking bone remodeling to autonomic and inflammatory processes.
- 3) This is an association study, requiring validation in a separate and equivalent patient population. This work is underway.

This work was supported by the US Army Medical Research and Materiel Command under Award No. W81XWH-08-1-0384. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army